ઇન્ડોકો રેમેડીઝ શેર કિંમત

ઇન્ડોકો રેમેડીઝ ઇન્વેસ્ટમેન્ટ રેટિંગ

• માસ્ટર રેટિંગ:

• Indoco Remedies Ltd. is a leading Indian pharmaceutical company specializing in the manufacturing and marketing of generic formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company focuses on quality, innovation, and compliance across various therapeutic segments. Indoco Remedies has an operating revenue of Rs. 1,773.21 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 7% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 32%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 45 which is a POOR score indicating inconsistency in earnings, a RS Rating of 23 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.